Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (32)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boize, R.
Right arrow Articles by Halimi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boize, R.
Right arrow Articles by Halimi, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 13, Issue 1 72-75, Copyright © 1998 by Oxford University Press


ORIGINAL ARTICLES

ApoE polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM?

R Boize, P Benhamou, P Corticelli, K Valenti, J Bosson and S Halimi
Department of Endocrinology, Department of Biochemistry and Department of Biomathematics, University Hospital, Grenoble, France; Corresponding author at: Service d'Endocrinologie Diabetologie Nutrition, CHU, BP217X, F-38043 Grenoble Cedex, France

Background: Chronic hyperglycaemia stands with diabetes duration as the main predicting factor for the development of nephropathy in insulin dependent diabetes mellitus (IDDM). In contrast, nephropathy in non-insulin-dependent diabetes mellitus (NIDDM) present with a different natural history and, as well as atherosclerosis, can precede diabetes diagnosis and even the onset of patient hyperglycaemia. The role of lipid abnormalities in this matter remains debated. Methods: We studied the prevalence of nephropathy (N+=urinary albumin excretion rate (UAE) >20 mg/d) in 134 Caucasian NIDDM patients ranked according to alipoprotein E (apoE) genotype (same distribution in 132 controls). Age, diabetes duration and sex ratio did not differ between N+ and N-. A patient with E2E4 (n=1) was excluded from the analysis. Results: The prevalence of nephropathy was significantly reduced in E2 allele carriers (36%, 8/22) vs 69% (77/111) in E2 non-carriers (P <0.01). Relative risk (RR) of E2 carriers developing nephropathy was 0.52 (95% CI=0.35-0.80). Both groups were comparable in terms of age (55±11 vs 57±11 years), diabetes duration (15 ±9vs 14±10 years) and prevalence of retinopathy (59 vs 48%). Similar results were observed when patients with diabetes duration longer than 8 years were studied (n=94). Conclusions: It has been largely established that low-density lipoprotein (LDL)-cholesterol level in E2 allele carriers (whether diabetic or not) was lower than in E2 non-carriers. The 2-fold increase of nephropathy in E2 non-carriers with NIDDM argues for a role for LDL in the development of human nephropathy in NIDDM patients. This result is in agreement with previous data established both in vitro and in vivo in animal models. These findings support evidence for the pathogenic and morphologic similarities between kidney disease and atherosclerosis in NIDDM patients. Key words: apolipoprotein E; coronaropathy; microalbuminuria; diabetic nephropathy; NIDDM
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
J. Guan, H.-L. Zhao, L. Baum, Y. Sui, L. He, H. Wong, F. M. M. Lai, P. C. Y. Tong, and J. C. N. Chan
Apolipoprotein E polymorphism and expression in type 2 diabetic patients with nephropathy: clinicopathological correlation
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1889 - 1895.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
C. C. Hsu, W. H. L. Kao, J. Coresh, J. S. Pankow, J. Marsh-Manzi, E. Boerwinkle, and M. S. Bray
Apolipoprotein E and Progression of Chronic Kidney Disease
JAMA, June 15, 2005; 293(23): 2892 - 2899.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. D. Breyer, E. Bottinger, F. C. Brosius III, T. M. Coffman, R. C. Harris, C. W. Heilig, K. Sharma, and for the AMDCC
Mouse Models of Diabetic Nephropathy
J. Am. Soc. Nephrol., January 1, 2005; 16(1): 27 - 45.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
E. N. Liberopoulos, G. A. Miltiadous, M. Cariolou, R. Kalaitzidis, K. C. Siamopoulos, and M. S. Elisaf
Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects
Nephrol. Dial. Transplant., August 1, 2004; 19(8): 2006 - 2012.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
S.-i. Araki, D. Koya, T. Makiishi, T. Sugimoto, M. Isono, R. Kikkawa, A. Kashiwagi, and M. Haneda
APOE Polymorphism and the Progression of Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes: Results of a prospective observational follow-up study
Diabetes Care, August 1, 2003; 26(8): 2416 - 2420.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S.-K. Ha, H. S. Park, K. W. Kim, S. J. Kim, D.-H. Kim, J. H. Kim, H. Y. Lee, and D. S. Han
Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus
Nephrol. Dial. Transplant., September 1, 1999; 14(9): 2144 - 2149.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.